 | • レポートコード：MRC2312MG04908 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のウイルス性胃腸炎治療薬市場規模と予測を収録しています。・世界のウイルス性胃腸炎治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界のウイルス性胃腸炎治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のウイルス性胃腸炎治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「抗生物質」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 ウイルス性胃腸炎治療薬のグローバル主要企業は、Pfizer、 AbbVie、 Bayer AG、 Sanofi S.A.、 AstraZeneca Plc.、 Abbott Laboratories、 GlaxoSmithKline Plc.、 Takeda Pharmaceutical Company Limited、 EliLilly and Company、 Amgen Inc、 C.H.Boehringer Sohn AG & Co.KG、 Daiichi Sankyo Company Limited、 Regeneron Pharmaceuticals lInc.、 Mylan N.V.、 Astellas Pharma Inc.、 Fresenius Kabi AGなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、ウイルス性胃腸炎治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のウイルス性胃腸炎治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界のウイルス性胃腸炎治療薬市場：タイプ別市場シェア、2022年 ・抗生物質、制酸剤、制吐剤、その他 世界のウイルス性胃腸炎治療薬市場：用途別、2018年-2023年、2024年-2029年 世界のウイルス性胃腸炎治療薬市場：用途別市場シェア、2022年 ・病院、診療所、その他 世界のウイルス性胃腸炎治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界のウイルス性胃腸炎治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるウイルス性胃腸炎治療薬のグローバル売上、2018年-2023年 ・主要企業におけるウイルス性胃腸炎治療薬のグローバル売上シェア、2022年 ・主要企業におけるウイルス性胃腸炎治療薬のグローバル販売量、2018年-2023年 ・主要企業におけるウイルス性胃腸炎治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Pfizer、 AbbVie、 Bayer AG、 Sanofi S.A.、 AstraZeneca Plc.、 Abbott Laboratories、 GlaxoSmithKline Plc.、 Takeda Pharmaceutical Company Limited、 EliLilly and Company、 Amgen Inc、 C.H.Boehringer Sohn AG & Co.KG、 Daiichi Sankyo Company Limited、 Regeneron Pharmaceuticals lInc.、 Mylan N.V.、 Astellas Pharma Inc.、 Fresenius Kabi AG ************************************************************* ・調査・分析レポートの概要 ウイルス性胃腸炎治療薬市場の定義 市場セグメント 世界のウイルス性胃腸炎治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のウイルス性胃腸炎治療薬市場規模 世界のウイルス性胃腸炎治療薬市場規模：2022年 VS 2029年 世界のウイルス性胃腸炎治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのウイルス性胃腸炎治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のウイルス性胃腸炎治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：抗生物質、制酸剤、制吐剤、その他 ウイルス性胃腸炎治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、その他 ウイルス性胃腸炎治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別ウイルス性胃腸炎治療薬市場規模 2022年と2029年 地域別ウイルス性胃腸炎治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Pfizer、 AbbVie、 Bayer AG、 Sanofi S.A.、 AstraZeneca Plc.、 Abbott Laboratories、 GlaxoSmithKline Plc.、 Takeda Pharmaceutical Company Limited、 EliLilly and Company、 Amgen Inc、 C.H.Boehringer Sohn AG & Co.KG、 Daiichi Sankyo Company Limited、 Regeneron Pharmaceuticals lInc.、 Mylan N.V.、 Astellas Pharma Inc.、 Fresenius Kabi AG ... |
This research report provides a comprehensive analysis of the Viral Gastroenteritis Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Viral Gastroenteritis Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Viral Gastroenteritis Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Viral Gastroenteritis Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Viral Gastroenteritis Drugs market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Viral Gastroenteritis Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Viral Gastroenteritis Drugs market was valued at US$ 41 million in 2022 and is projected to reach US$ 55 million by 2029, at a CAGR of 4.3% during the forecast period.
The Viral Gastroenteritis Drugs market is influenced by several trends that are shaping the development and availability of medications for this condition. Viral gastroenteritis, commonly known as the stomach flu, is caused by various viruses and is characterized by symptoms such as diarrhea, vomiting, abdominal pain, and fever.One major trend in the Viral Gastroenteritis Drugs market is the focus on supportive care and symptom management. Currently, there are no specific antiviral drugs available for the treatment of viral gastroenteritis. Therefore, the primary approach is to manage symptoms such as dehydration, nausea, and diarrhea. Oral rehydration solutions, anti-emetic medications, and anti-diarrheal agents are commonly used to alleviate symptoms and improve patient comfort.
Key Features:
The research report on the Viral Gastroenteritis Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Viral Gastroenteritis Drugs market.
Market Overview: The report provides a comprehensive overview of the Viral Gastroenteritis Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Antibiotic, Antacids), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Viral Gastroenteritis Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Viral Gastroenteritis Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Viral Gastroenteritis Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Viral Gastroenteritis Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Viral Gastroenteritis Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Viral Gastroenteritis Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Viral Gastroenteritis Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Viral Gastroenteritis Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Viral Gastroenteritis Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Antibiotic
Antacids
Antikinetic Agent
Other
Market segment by Application
Hospital
Clinic
Other
Global Viral Gastroenteritis Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Pfizer
AbbVie
Bayer AG
Sanofi S.A.
AstraZeneca Plc.
Abbott Laboratories
GlaxoSmithKline Plc.
Takeda Pharmaceutical Company Limited
EliLilly and Company
Amgen Inc
C.H.Boehringer Sohn AG & Co.KG
Daiichi Sankyo Company Limited
Regeneron Pharmaceuticals lInc.
Mylan N.V.
Astellas Pharma Inc.
Fresenius Kabi AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Viral Gastroenteritis Drugs, market overview.
Chapter 2: Global Viral Gastroenteritis Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Viral Gastroenteritis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Viral Gastroenteritis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Viral Gastroenteritis Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Viral Gastroenteritis Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Viral Gastroenteritis Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Viral Gastroenteritis Drugs Overall Market Size
2.1 Global Viral Gastroenteritis Drugs Market Size: 2022 VS 2029
2.2 Global Viral Gastroenteritis Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Viral Gastroenteritis Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Viral Gastroenteritis Drugs Players in Global Market
3.2 Top Global Viral Gastroenteritis Drugs Companies Ranked by Revenue
3.3 Global Viral Gastroenteritis Drugs Revenue by Companies
3.4 Global Viral Gastroenteritis Drugs Sales by Companies
3.5 Global Viral Gastroenteritis Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Viral Gastroenteritis Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Viral Gastroenteritis Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Viral Gastroenteritis Drugs Players in Global Market
3.8.1 List of Global Tier 1 Viral Gastroenteritis Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Viral Gastroenteritis Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Viral Gastroenteritis Drugs Market Size Markets, 2022 & 2029
4.1.2 Antibiotic
4.1.3 Antacids
4.1.4 Antikinetic Agent
4.1.5 Other
4.2 By Type – Global Viral Gastroenteritis Drugs Revenue & Forecasts
4.2.1 By Type – Global Viral Gastroenteritis Drugs Revenue, 2018-2023
4.2.2 By Type – Global Viral Gastroenteritis Drugs Revenue, 2024-2029
4.2.3 By Type – Global Viral Gastroenteritis Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Viral Gastroenteritis Drugs Sales & Forecasts
4.3.1 By Type – Global Viral Gastroenteritis Drugs Sales, 2018-2023
4.3.2 By Type – Global Viral Gastroenteritis Drugs Sales, 2024-2029
4.3.3 By Type – Global Viral Gastroenteritis Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Viral Gastroenteritis Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Viral Gastroenteritis Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application – Global Viral Gastroenteritis Drugs Revenue & Forecasts
5.2.1 By Application – Global Viral Gastroenteritis Drugs Revenue, 2018-2023
5.2.2 By Application – Global Viral Gastroenteritis Drugs Revenue, 2024-2029
5.2.3 By Application – Global Viral Gastroenteritis Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Viral Gastroenteritis Drugs Sales & Forecasts
5.3.1 By Application – Global Viral Gastroenteritis Drugs Sales, 2018-2023
5.3.2 By Application – Global Viral Gastroenteritis Drugs Sales, 2024-2029
5.3.3 By Application – Global Viral Gastroenteritis Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Viral Gastroenteritis Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Viral Gastroenteritis Drugs Market Size, 2022 & 2029
6.2 By Region – Global Viral Gastroenteritis Drugs Revenue & Forecasts
6.2.1 By Region – Global Viral Gastroenteritis Drugs Revenue, 2018-2023
6.2.2 By Region – Global Viral Gastroenteritis Drugs Revenue, 2024-2029
6.2.3 By Region – Global Viral Gastroenteritis Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Viral Gastroenteritis Drugs Sales & Forecasts
6.3.1 By Region – Global Viral Gastroenteritis Drugs Sales, 2018-2023
6.3.2 By Region – Global Viral Gastroenteritis Drugs Sales, 2024-2029
6.3.3 By Region – Global Viral Gastroenteritis Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Viral Gastroenteritis Drugs Revenue, 2018-2029
6.4.2 By Country – North America Viral Gastroenteritis Drugs Sales, 2018-2029
6.4.3 US Viral Gastroenteritis Drugs Market Size, 2018-2029
6.4.4 Canada Viral Gastroenteritis Drugs Market Size, 2018-2029
6.4.5 Mexico Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Viral Gastroenteritis Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Viral Gastroenteritis Drugs Sales, 2018-2029
6.5.3 Germany Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.4 France Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.5 U.K. Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.6 Italy Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.7 Russia Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Viral Gastroenteritis Drugs Market Size, 2018-2029
6.5.9 Benelux Viral Gastroenteritis Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Viral Gastroenteritis Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Viral Gastroenteritis Drugs Sales, 2018-2029
6.6.3 China Viral Gastroenteritis Drugs Market Size, 2018-2029
6.6.4 Japan Viral Gastroenteritis Drugs Market Size, 2018-2029
6.6.5 South Korea Viral Gastroenteritis Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Viral Gastroenteritis Drugs Market Size, 2018-2029
6.6.7 India Viral Gastroenteritis Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Viral Gastroenteritis Drugs Revenue, 2018-2029
6.7.2 By Country – South America Viral Gastroenteritis Drugs Sales, 2018-2029
6.7.3 Brazil Viral Gastroenteritis Drugs Market Size, 2018-2029
6.7.4 Argentina Viral Gastroenteritis Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Viral Gastroenteritis Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Viral Gastroenteritis Drugs Sales, 2018-2029
6.8.3 Turkey Viral Gastroenteritis Drugs Market Size, 2018-2029
6.8.4 Israel Viral Gastroenteritis Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Viral Gastroenteritis Drugs Market Size, 2018-2029
6.8.6 UAE Viral Gastroenteritis Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Viral Gastroenteritis Drugs Major Product Offerings
7.1.4 Pfizer Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 AbbVie
7.2.1 AbbVie Company Summary
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Viral Gastroenteritis Drugs Major Product Offerings
7.2.4 AbbVie Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Key News & Latest Developments
7.3 Bayer AG
7.3.1 Bayer AG Company Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Viral Gastroenteritis Drugs Major Product Offerings
7.3.4 Bayer AG Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Bayer AG Key News & Latest Developments
7.4 Sanofi S.A.
7.4.1 Sanofi S.A. Company Summary
7.4.2 Sanofi S.A. Business Overview
7.4.3 Sanofi S.A. Viral Gastroenteritis Drugs Major Product Offerings
7.4.4 Sanofi S.A. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi S.A. Key News & Latest Developments
7.5 AstraZeneca Plc.
7.5.1 AstraZeneca Plc. Company Summary
7.5.2 AstraZeneca Plc. Business Overview
7.5.3 AstraZeneca Plc. Viral Gastroenteritis Drugs Major Product Offerings
7.5.4 AstraZeneca Plc. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.5.5 AstraZeneca Plc. Key News & Latest Developments
7.6 Abbott Laboratories
7.6.1 Abbott Laboratories Company Summary
7.6.2 Abbott Laboratories Business Overview
7.6.3 Abbott Laboratories Viral Gastroenteritis Drugs Major Product Offerings
7.6.4 Abbott Laboratories Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Laboratories Key News & Latest Developments
7.7 GlaxoSmithKline Plc.
7.7.1 GlaxoSmithKline Plc. Company Summary
7.7.2 GlaxoSmithKline Plc. Business Overview
7.7.3 GlaxoSmithKline Plc. Viral Gastroenteritis Drugs Major Product Offerings
7.7.4 GlaxoSmithKline Plc. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.7.5 GlaxoSmithKline Plc. Key News & Latest Developments
7.8 Takeda Pharmaceutical Company Limited
7.8.1 Takeda Pharmaceutical Company Limited Company Summary
7.8.2 Takeda Pharmaceutical Company Limited Business Overview
7.8.3 Takeda Pharmaceutical Company Limited Viral Gastroenteritis Drugs Major Product Offerings
7.8.4 Takeda Pharmaceutical Company Limited Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.9 EliLilly and Company
7.9.1 EliLilly and Company Company Summary
7.9.2 EliLilly and Company Business Overview
7.9.3 EliLilly and Company Viral Gastroenteritis Drugs Major Product Offerings
7.9.4 EliLilly and Company Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.9.5 EliLilly and Company Key News & Latest Developments
7.10 Amgen Inc
7.10.1 Amgen Inc Company Summary
7.10.2 Amgen Inc Business Overview
7.10.3 Amgen Inc Viral Gastroenteritis Drugs Major Product Offerings
7.10.4 Amgen Inc Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Amgen Inc Key News & Latest Developments
7.11 C.H.Boehringer Sohn AG & Co.KG
7.11.1 C.H.Boehringer Sohn AG & Co.KG Company Summary
7.11.2 C.H.Boehringer Sohn AG & Co.KG Business Overview
7.11.3 C.H.Boehringer Sohn AG & Co.KG Viral Gastroenteritis Drugs Major Product Offerings
7.11.4 C.H.Boehringer Sohn AG & Co.KG Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.11.5 C.H.Boehringer Sohn AG & Co.KG Key News & Latest Developments
7.12 Daiichi Sankyo Company Limited
7.12.1 Daiichi Sankyo Company Limited Company Summary
7.12.2 Daiichi Sankyo Company Limited Business Overview
7.12.3 Daiichi Sankyo Company Limited Viral Gastroenteritis Drugs Major Product Offerings
7.12.4 Daiichi Sankyo Company Limited Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Daiichi Sankyo Company Limited Key News & Latest Developments
7.13 Regeneron Pharmaceuticals lInc.
7.13.1 Regeneron Pharmaceuticals lInc. Company Summary
7.13.2 Regeneron Pharmaceuticals lInc. Business Overview
7.13.3 Regeneron Pharmaceuticals lInc. Viral Gastroenteritis Drugs Major Product Offerings
7.13.4 Regeneron Pharmaceuticals lInc. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Regeneron Pharmaceuticals lInc. Key News & Latest Developments
7.14 Mylan N.V.
7.14.1 Mylan N.V. Company Summary
7.14.2 Mylan N.V. Business Overview
7.14.3 Mylan N.V. Viral Gastroenteritis Drugs Major Product Offerings
7.14.4 Mylan N.V. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Mylan N.V. Key News & Latest Developments
7.15 Astellas Pharma Inc.
7.15.1 Astellas Pharma Inc. Company Summary
7.15.2 Astellas Pharma Inc. Business Overview
7.15.3 Astellas Pharma Inc. Viral Gastroenteritis Drugs Major Product Offerings
7.15.4 Astellas Pharma Inc. Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Astellas Pharma Inc. Key News & Latest Developments
7.16 Fresenius Kabi AG
7.16.1 Fresenius Kabi AG Company Summary
7.16.2 Fresenius Kabi AG Business Overview
7.16.3 Fresenius Kabi AG Viral Gastroenteritis Drugs Major Product Offerings
7.16.4 Fresenius Kabi AG Viral Gastroenteritis Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Fresenius Kabi AG Key News & Latest Developments
8 Global Viral Gastroenteritis Drugs Production Capacity, Analysis
8.1 Global Viral Gastroenteritis Drugs Production Capacity, 2018-2029
8.2 Viral Gastroenteritis Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Viral Gastroenteritis Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Viral Gastroenteritis Drugs Supply Chain Analysis
10.1 Viral Gastroenteritis Drugs Industry Value Chain
10.2 Viral Gastroenteritis Drugs Upstream Market
10.3 Viral Gastroenteritis Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Viral Gastroenteritis Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
